Assessing the Evolving Role of GLP1-RAs to Reduce Cardiovascular Risk: Emerging Evidence, Evolving Guidance, and Expert Perspectives

1.00 CME
1.00 ANCC
60 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Assessing the Evolving Role of GLP1-RAs to Reduce Cardiovascular Risk: Emerging Evidence, Evolving Guidance, and Expert Perspectives

PACE logo CMHC logo This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress.

Supported by an educational grant from Novo Nordisk

Program Overview

Release Date: January 18, 2023
Expiration Date: January 18, 2024

GLP-1 RAs have carved an important role in the management of patients with type 2 diabetes (T2D), not only in glycemic control, but also in reducing cardiovascular and renal risk. The evolving evidence with GLP-1 RA in this setting has led to important studies and guideline changes, all with significant implications for patient management. Given the breadth of the evidence, it might be challenging to interpret these advances, and during this symposium, our experts will discuss how this new evidence impacts the individualization of therapy for T2D patients.


Learning Objectives

After completing this activity, the participant should be better able to:

  • Discuss the mechanisms of action and different properties of GLP-1 RAs
  • Summarize the efficacy and safety of GLP-1 RAs, alone or in combination, for the management of T2DM
  • Review the current evidence from CVOTs and real-world studies with GLP-1 RAs and their practice implications in managing T2DM patients with CVD or at CVD risk
  • List recent guideline updates about the individualization of T2DM therapy in patients with existing CVD or CVD risk
  • Select individualized treatment strategies for patients with T2DM that optimize glycemic control and reduce overall CVD risk


Chair

Aroda headshot
Vanita R. Aroda, MD
Director, Diabetes Clinical Research, Brigham and Women’s Hospital
Boston, MA

Dr. Aroda discloses the following:
Consultant, Advisor, Speaker: Applied Therapeutics, Fractyl, Novo Nordisk, Pfizer, Sanofi
Researcher: Applied Therapeutics, Eli Lilly, Premier/Fractyl, Novo Nordisk, Sanofi

Faculty

McDonnell headshot
Marie E. McDonnell, MD
Chief of Diabetes Section and Director of the Diabetes Program, Brigham & Women's Hospital
Boston, MA

Dr. McDonnell discloses the following:
Other: Eli-Lilly
Consultant, Advisor, Speaker: Everlywell, Inc

Plutzky headshot
Jorge Plutzky, MD
Director, Preventive Cardiology, Brigham and Women's Hospital
Boston, MA

Dr. Plutzky has no relevant financial relationship(s) with ineligible companies to disclose.


JOINT PROVIDERSHIP STATEMENT

JAC logoCMHC logoPACE logo

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC

abim Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

NURSING CONTINUING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

PHARMACY CONTINUING EDUCATION

PACE designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-23-016-H01-P. Type of activity: Application

DIETITIAN CONTINUING EDUCATION

This program offers 1.0 CPEUs for dietitians.


INSTRUCTIONS FOR PARTICIPATION

In order to receive credit, participants must complete the activity in its entirety. Participants must also score at least a 75% on the posttest and submit it, along with the credit application and evaluation form.

There are no fees for participating in this activity.

For additional information about the accreditation of this activity, please visit https://partnersed.com


DISCLOSURES

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The CMHC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

DISCLOSURE OF CONFLICT OF INTEREST

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.